AIM:To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin. METHODS:F o u r t e e n p a t i e n t s ( m e d i a n a g e 5 6 years) with advanced CRC, all having progressed after oxaliplatin-and irinotecan-based combination chemotherapy, were enrolled in this study. Patients were treated with 2 h infusion of irinotecan 150 mg/m 2 on d 1, plus bevacizumab 5 mg/kg iv infusion for 90 min on d 2, and iv injection of LV 20 mg/m 2 followed by a bolus of 5-FU 400 mg/m 2 and then 22 h continuous infusion of 600 mg/m 2 given on two consecutive days every 14 d. RESULTS:The median number of cycles of chemotherapy was six (range 3-12). The response rate was 28.5%, one patient had a complete response, and three patients had a partial response. Eight patients had stable disease. The median time to progression was 3.9 mo (95% CI 2.0-8.7), and the median overall survival was 10.9 mo (95% CI 9.6-12.1). Grade 3/4 neutropenia occurred in five patients, and two of these developed neutropenic fever. Grade 3 hematuria and hematochezia occurred in one. Grade 2 proteinuria occurred in two patients. However, hypertension, bowel perforation or thromboembolic events did not occur in a total of 90 cycles. CONCLUSION:Bevacizumab with FOLFIRI is well tolerated and a feasible treatment in patients with heavily treated advanced CRC. www.wjgnet.com regimens [21] . In a phase 2 trial of treatment of CRC, the addition of bevacizumab to FU/LV increased the response rate, the median time to disease progression, and the median duration of survival [22] . Recently, it has been shown in randomized phase Ⅲ trials that bevacizumab, when combined with irinotecan plus bolus FU/LV in the firstline treatment of metastatic CRC, and with oxaliplatin plus continuous FU/LV (FOLFOX) in second-line treatment leads to an increased median survival, progression-free survival (PFS), and response rate compared with cytotoxic chemotherapy alone [23,24] . The goal of this trial was to evaluate the safety and activity of bevacizumab plus LV, 5-FU and irinotecan (FOLFIRI) in patients with advanced CRC that had progressed after treatment with both irinotecan-and oxaliplatin-based chemotherapy regimens. MATERIALS AND METHODS Eligibility criteriaThe eligibility criteria were as follows: histologically confir med CRC (adenocarcinoma), bidimensionally measurable disease, no secondary malignancy, age > 18 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, and a life expectancy of > 3 mo. Adequate hematological, hepatic and renal function (including urinary excretion of no more than 500 mg protein/d) were also required. Patients should have had and failed both oxaliplatin-and irinotecan-based treatment prior to enrolment. Failure due to significant intolerance to either drug was allowed.Exclusion criteria included thromboembolism that required thera...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.